Literature DB >> 18471721

Transduodenal sphincteroplasty in the management of sphincter of Oddi dysfunction and pancreas divisum in the modern era.

Katherine A Morgan1, Joseph Romagnuolo, David B Adams.   

Abstract

BACKGROUND: Surgical management of sphincter of Oddi dysfunction and pancreas divisum is controversial. In the modern era of therapeutic endoscopy, pain persisting despite endoscopic sphincterotomy and anatomy that makes the ampulla endoscopically inaccessible prompt referral for surgical transduodenal sphincteroplasty (TS). A retrospective review of sphincter of Oddi dysfunction and pancreas divisum patients who underwent TS for refractory pain in a recent time period was undertaken. STUDY
DESIGN: The medical records of all patients who underwent TS for sphincter of Oddi dysfunction and pancreas divisum at the Medical University of South Carolina between January 2001 and December 2005 were reviewed. Longterm outcomes were assessed by a standardized written questionnaire and the SF-36 version 2 Quality of Life Survey.
RESULTS: Sixty-eight patients underwent TS (median age 43 years, 54 women). Fifty-one had earlier endoscopic sphincterotomy; 17, with previous gastric surgery, did not. Operative morbidity was 10.3%, with no mortality. Forty-five patients (66%) completed the questionnaire; 62% had improvement in pain, without reintervention, over a median followup of 42.5 months (range 16 to 75 months). There was a trend toward more favorable outcomes in patients with earlier gastric surgery (no previous endoscopic sphincterotomy) compared with others (90% versus 54%, p=0.06). Multivariate analysis showed chronic pancreatitis (odds ratio 0.11 [95% CI 0.02 to 0.68; p=0.02]) and younger age (odds ratio 3.9 [95% CI 1.32 to 11.53; p=0.01] per decade) were independent predictors of poorer outcomes.
CONCLUSIONS: Good longterm outcomes with low operative morbidity can be obtained with TS in selected patients, including those with postgastric bypass, but younger age and chronic pancreatitis appear to predict poorer outcomes.

Entities:  

Mesh:

Year:  2008        PMID: 18471721     DOI: 10.1016/j.jamcollsurg.2007.12.032

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  5 in total

Review 1.  Current status and prerequisites for natural orifice translumenal endoscopic surgery (NOTES).

Authors:  Morimasa Tomikawa; Hao Xu; Makoto Hashizume
Journal:  Surg Today       Date:  2010-09-25       Impact factor: 2.549

2.  Prior surgery determines islet yield and insulin requirement in patients with chronic pancreatitis.

Authors:  Hongjun Wang; Krupa D Desai; Huansheng Dong; Stefanie Owzarski; Joseph Romagnuolo; Katherine A Morgan; David B Adams
Journal:  Transplantation       Date:  2013-04-27       Impact factor: 4.939

3.  Total pancreatectomy with islet autotransplantation: summary of a National Institute of Diabetes and Digestive and Kidney diseases workshop.

Authors:  Melena D Bellin; Andres Gelrud; Guillermo Arreaza-Rubin; Ty B Dunn; Abhinav Humar; Katherine A Morgan; Bashoo Naziruddin; Cristiana Rastellini; Michael R Rickels; Sarah J Schwarzenberg; Dana K Andersen
Journal:  Pancreas       Date:  2014-11       Impact factor: 3.327

4.  Total pancreatectomy with islet autotransplantation: summary of an NIDDK workshop.

Authors:  Melena D Bellin; Andres Gelrud; Guillermo Arreaza-Rubin; Ty B Dunn; Abhinav Humar; Katherine A Morgan; Bashoo Naziruddin; Cristiana Rastellini; Michael R Rickels; Sarah J Schwarzenberg; Dana K Andersen
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

5.  Rigid and flexible endoscopic rendezvous in spatium peritonealis may be an effective tactic for laparoscopic megasplenectomy: significant implications for pure natural orifice translumenal endoscopic surgery.

Authors:  Morimasa Tomikawa; Tomohiko Akahoshi; Nao Kinjo; Hideo Uehara; Naotaka Hashimoto; Yoshihiro Nagao; Masahiro Kamori; Ryuichi Kumashiro; Yoshihiko Maehara; Makoto Hashizume
Journal:  Surg Endosc       Date:  2012-06-08       Impact factor: 4.584

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.